Hybrid closed-loop therapy significantly improved maternal glycemic control during pregnancy in people with type 1 diabetes, providing a clinical advantage beyond that achieved with continuous glucose monitoring (CGM) and insulin-pump therapy, shows the AiDAPT randomized controlled trial.
The results were presented for the first time at this year's European Association for the Study of Diabetes (EASD) meeting and published simultaneously in The New England Journal of Medicine (NEJM).
"The importance of these findings cannot be understated," said Satish K. Garg, MD, and Sarit Polsky, MD, from the Barbara Davis Center for Diabetes at the University of Colorado, Anschutz, who wrote the editorial accompanying the study. "Clearly, closed-loop systems have changed the landscape of diabetes care in nonpregnant populations...the AiDAPT trial provides hope that this landscape may also be altered for the better for pregnant persons with type 1 diabetes," they write.
